Negative result

Understanding a negative result

A guide to understanding risk and taking action

Health. Illuminated.

Negative result

Understanding your Myriad MyRisk
hereditary cancer test result

Breast cancer RiskScore™

™

You may or may not see a breast cancer RiskScore and/or a Tyrer-Cuzick breast cancer risk assessment in thissection of the report. This is calculated for women whomeet certain criteria and have never been diagnosed withbreast cancer themselves.

CONFIDENTIAL*54501229*
54501229

MyRisk Genetic Result

Name: Pt Last Name, Pt First Name

DOB: Dec 03, 1981

Accession #: 07007251-BLD

Report Date: Dec 03, 2021

Breast Cancer RiskScore®

Breast Cancer
RiskScore®:

RESULT:

12.1%

12.1% Remaining Lifetime Breast Cancer Risk
0.6% 5-Year Breast Cancer Risk

Remaining Lifetime Breast Cancer Risk (Age-Adjusted)
GeneralPopulation

Your Myriad Genetics MyRisk Hereditary Cancer test has three main sections which
are summarized in the banner on the first page. Throughout the report, these
sections can be identified by the title on the top left of each page of the report.

0Your negative result DOES NOT mean that other relatives, suchas your brothers and sisters, parents, aunts and uncles, cousins,or other family members do not have a harmful genetic changethat could increase their risk for cancer. If there is a family
history of cancer, your relatives should still discuss their history
with their own health care providers.

20

25

30

35

40

45

50

The breast cancer RiskScore provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate at or above 20% is
associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening andadditional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying MyRisk Medical
Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration ofmodified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick,
Claus, and Gail.
TYRER-CUZICK BREAST CANCER RISK CALCULATION
5-YEAR BREAST CANCER RISK: 0.6%

The National Comprehensive Cancer Network (NCCN) provides medical management recommendations for women with an estimatedremaining lifetime breast cancer risk greater than 20% based on Tyrer-Cuzick. These recommendations are summarized on the MyRisk
Management Tool (MMT). If an MMT is not included with this report, current management recommendations from the NCCN Breast
Cancer Screening and Diagnosis panel can be accessed at www.nccn.org. Version 7.02 of the Tyrer-Cuzick model was used for this risk
estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials website, http://www.ems-trials.org/
riskevaluator.

Clinical & cancer
family history information
CONFIDENTIAL*54501229*
54501229

MyRiskTM

Hereditary Cancer Test

MyRisk Genetic Result
RECEIVING HEALTHCARE PROVIDER

SPECIMEN

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1981

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

PATIENT

Dec 03, 2021

Name:

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007251-BLD

Requisition #: 90026818

The Clinical & Cancer Family History Information section
reviews the medical information that your healthcare
provider gave us about you and your family. Certain typesof cancer in the family, or cancers diagnosed at early ages
can indicate that someone may have an elevated risk,even if no clinically significant mutations are found.

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

BREAST CANCER RISKSCORE : REMAINING LIFETIME RISK 12.1%®

See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIEDBASED ON THE CLINICAL HISTORY PROVIDEDYour genetic result was NEGATIVE!

If a variant of uncertain clinical significance (VUS) was identified,
it will also be listed in the genetic result section. A VUS is a
genetic change that may or may not be contributing to yourcancer risk. We are committed to identifying new and relevant
information so that we can better understand these genetic
changes and what they mean for your cancer risk. If updated
information is available about your specific VUS, that information
will be shared with your healthcare provider. A VUS is notconsidered to be clinically actionable so medical care decisions
should not be made based on a VUS.

15

BREAST CANCER RISKSCORE INTERPRETATION

2This means that no clinically significant mutations were found inany of the genes analyzed as part of your testing. This does notmean that you have no cancer risk; it means that you did not inherita harmful genetic change identified in any of the genes analyzed.
Additionally, you cannot pass a clinically significant mutation inthese genes to your children.

10

REMAINING LIFETIME BREAST CANCER RISK: 12.0%

3 Management tool

The MyRisk test looks at multiple genes associated withhereditary cancer risk. When a gene has a clinically significant
mutation, or harmful change, there is a higher chance for certain
cancers to develop. A list of the genes evaluated on your test
can be found in this section of your report. The gene table on our
website includes information about each gene and the cancers
with which it is associated.

5®

2 Clinical & cancer family history information

Genetic result

12.1%

This Patient

1 Genetic result

1

20% Risk
Threshold

12.9%

CONFIDENTIAL*54501229*
54501229

MyRiskTM

Hereditary Cancer Test

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

Clinical & Cancer Family History Information
SPECIMEN

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1981

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

PATIENT

Dec 03, 2021

Name:

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007251-BLD

Requisition #: 90026818
PERSONAL / FAMILY CANCER HISTORY SUMMARYFAMILY MEMBERCANCER / CLINICAL DIAGNOSIS

Patient

AGE AT DIAGNOSISNone

PATIENT CLINICAL HISTORY SUMMARY
Woman's age

40

Ancestry

White/Non-Hispanic- HRT: Treatment Type

N/A

Height5 ft 7 in- HRT: Current user

N/A

Weight175 lbs- Number of years ago started

N/A

Age of menarche

13- Additional years of intended use

N/A

Patient's menopausal status

Pre-menopausal- Age of onset

Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.

MyRisk Genetic Result
Page 3 of 4

RECEIVING HEALTHCARE PROVIDER

Hormone Replacement Therapy (HRT)- HRT: Past user

N/A

Age of first live birth

No

N/A

- Number of years ago ended

27

N/A

Breast biopsy

No Benign Disease

NUMBER OF PATIENT'S FEMALE RELATIVESADDITIONAL FINDINGS: VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Daughters

1

Sisters2

Maternal Aunts

2

Paternal Aunts

2

There are currently insufficient data to determine if these variants cause increased risk.
GENE

VARIANT(S) OF UNCERTAIN SIGNIFICANCEINTERPRETATION

STK11

c.961C>G (p.Pro321Ala)

Uncertain Clinical Significance

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase anindividual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants(Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do
not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient
medical management beyond what is indicated by the personal and family history and any other clinically significant findings.
TM
Variant Classification: Myriad's myVision Variant Classification Program performs ongoing evaluations of variant classifications. In certain
cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When
new evidence about a variant is identified and determined to result in clinical significance and management change, that information willautomatically be made available to the healthcare provider through an amended report.

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

MyRisk Genetic Result
Page 1 of 4

Negative results with SINGLE-SITE testing: If a member of yourfamily has tested positive for a clinically significant mutation, yourprovider may have ordered testing for only that specific genetic
change. This is known as single-site testing. If you get a negative
single-site test result, you DO NOT carry the same clinicallysignificant mutation found in your relative. Since single-site testing
does not look for other genetic changes or assess risk from family
history, this is not a comprehensive risk assessment.

3

Management tool

In addition to your negative genetic test result, we did not
identify any recommendations for changes to your medicalcare based on the personal and family history we received
from your healthcare provider. If you received RiskScore and/or a Tyrer-Cuzick breast cancer risk assessment, it will show
your estimated lifetime risk of developing breast cancer. Risk
below 20% is generally not considered clinically actionable,
while risk above 20% suggests that additional breast
screening is recommended.
Personal and family histories can change over time, so it
is important to keep your healthcare providers up to dateregarding any changes.

CONFIDENTIAL*54501229*
54501229

MyRiskTM® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

Hereditary Cancer Test

MyRisk Management Tool
RECEIVING HEALTHCARE PROVIDER

SPECIMEN

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1981

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

Clinical Information
Page 1 of 2

PATIENT

Dec 03, 2021

Name:

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007251-BLD

Requisition #: 90026818

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

BREAST CANCER RISKSCORE®: REMAINING LIFETIME RISK 12.1%
See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIEDBASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.
No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may
still be increased over the general population. See information below.
Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.
ADDITIONAL FINDINGS: VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIEDTYRER-CUZICK BREAST CANCER RISK CALCULATIONREMAINING LIFETIME BREAST CANCER RISK: 12.0%

5-YEAR BREAST CANCER RISK: 0.6%

The Tyrer-Cuzick breast cancer risk estimate is only calculated for women who meet the following criteria: 1) age is younger than 85 years,2) no known mutation or inconclusive result has been found in the woman or any of her relatives, and 3) the sample was submitted with acurrent Test Request Form that includes all of the fields required to collect the information used in the calculation, and the provider has
not indicated on the Test Request Form that the Tyrer-Cuzick calculation is not appropriate for the patient. Version 7.02 of the TyrerCuzick model was used for this risk estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials
website, http://www.ems-trials.org/riskevaluator.

Notes for Personalized Management:

ResourcesYour healthcare provider is always your primary resource. You can findadditional information and educational material at www.mysupport360.com.
You can request a consultation with a genetic counselor at Myriad by going tomy.myriad.com/consults. During your consultation, the genetic counselor canhelp you understand your report and the implications of your results.
To view the full list of genes available on the MyRisk™ panel, please visit:www.myriadmyrisk.com/gene-table/

Next steps
Schedule any follow-up appointments and/or obtain referrals toappropriate specialists
Speak with your relatives about your results and encourage them to see
their healthcare provider about cancer prevention and genetic testing
Consider speaking with a clinical genetic counselor or other genetics
expert in your community about your test result and family history

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT
84108
myriad.com

Myriad, the Myriad logo, Myriad myRisk, the Myriad myRisk logo, riskScore
the riskScore logo, mySupport360, and the mySupport360 logo are either
trademarks or registered trademarks of Myriad Genetics, Inc. in the UnitedStates and other jurisdictions.
©2022, Myriad Genetic Laboratories, Inc.
MGMRHCNEGPET / 02-22